Oramed Pharmaceuticals Inc. ORMP NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score

69/100

4/7 Pass

SharesGrow Intrinsic Value

$37.98

+894.2%

Income Statement Balance Sheet Cash Flow Statement

Annual Quarterly

Oramed Pharmaceuticals Inc. (ORMP) generated $-4.05M in operating cash flow for quarter ending 2025-12-31. After capital expenditures of $4K, free cash flow was $-4.05M.

Cash conversion ratio was 2.03x, indicating earnings are backed by cash.

The company returned $5.3M in share buybacks to shareholders during the quarter.

Criteria supported by this page:

HEALTH (100/100, Pass) — demonstrate the company can comfortably service its debt
MOAT (0/100, Fail) — limited free cash flow weakens the competitive position
INCOME (100/100) — Cash conversion ratio was 2.03x confirms earnings are backed by real cash flow

Overall SharesGrow Score: 69/100 with 4/7 criteria passed.

SharesGrow 7-Criteria Score

69/100

SG Score

View full scorecard →

✓

VALUE

100/100

Price-to-Earnings & upside

→ Valuation

✓

FUTURE

75/100

Analyst consensus

→ Forecast

PAST

50/100

→ Income

✓

HEALTH

100/100

Debt-to-Equity & liquidity

Proven by this page

✗

MOAT

0/100

Proven by this page

GROWTH

58/100

→ Income

✓

INCOME

100/100

→ Income

Oramed Pharmaceuticals Inc. Cash Flow History

Metric	TTM	Q4 FY2025	Q3 FY2025	Q2 FY2025	Q1 FY2025
Operating Cash Flow	$-13.12M	$-4.05M	$-1.99M	$-3.57M	$-3.52M
Capital Expenditure	$-11.32K	$-4K	$-289.00	$-4.03K	$-3K
Free Cash Flow	$-13.13M	$-4.05M	$-1.99M	$-3.57M	$-3.52M